Europe Cannabis Regulation

One of Europe's more liberal markets, easing access further and building an export sector.

A pilot becoming permanent — and a significant European producer and exporter.

Europe's largest medical market, transformed by the 2024 MedCanG reform — and adult possession now legal.

Legal since 2017, with products finally reaching patients in 2024 and production ramping up.

A legal medical market since 2015, tightly controlled through government and military production.

Europe's first medical system and a leading exporter, now formalising its coffeeshop supply through a national experiment.

Strong growth then a telemedicine-driven contraction — the EU's clearest regulatory-risk case study.

Europe's largest cannabis exporter, with tightly restricted domestic patient access.

Medical legal since 2011 and home to Europe's most extensive adult-use trials, with full legalisation now drafting.

Europe's second-largest medical market, almost entirely private-pay and clinic-driven.

Europe's largest untapped medical market — moving from trial to a permanent framework by 2026.

A narrow access programme for three conditions, with few patients treated in practice.

Adult possession and home cultivation legal since 2023; commercial retail not yet in place.

First EU member state to legalise adult use — supplied through non-profit associations.

A major European production and export hub, though domestic patient access is very limited.

A major producer and exporter where patients still have no legal access — a conservative medical decree is pending.

Medical access legalised in 2024 — a significant emerging Eastern European market.

Medical access limited to dronabinol preparations; flower is not available to patients.

Only pure CBD in magistral preparations is permitted; other medical cannabis is not allowed.

Legal since 2015 but stalled by bureaucracy and cost, with no products currently available.

A legal framework exists, but practical patient access is only via exceptional ministerial approval.

Accessible only through a complex special-permit process via the State Agency of Medicines.

A strictly controlled unlicensed medicine requiring a Fimea special permit; prescribing has declined.

A 2019 framework that remains slow to implement, with no patients treated and cultivation prohibited.

Unregistered products available since 2016 through an approval-exemption, via hospital pharmacies.

An extremely narrow 2013 law with no practical patient access; expansion was rejected in 2019.

A 2025 framework regarded as one of Europe's most progressive — after years of inaccessibility.

Available only through a rigorous individual-licence process, with numbers slowly rising.